HeartFlow Analysis vs Cardiomo

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by HeartFlow
VS
by Cardiomo, Inc.

AI Verdict

HeartFlow Analysis and Cardiomo are adjacent tools in cardiovascular care, both leveraging AI but with distinct applications. HeartFlow focuses on non-invasive diagnostic assessment of coronary artery disease using CT scans to create 3D models and analyze blood flow, aiding in treatment planning for established conditions. Cardiomo, conversely, provides continuous, remote heart health monitoring via a wearable device, emphasizing early detection of cardiovascular events and real-time alerts for ongoing patient management and preventative care.

Choose HeartFlow Analysis if…

Choose HeartFlow Analysis if you need a non-invasive, highly accurate diagnostic tool to assess the functional impact of coronary artery blockages. It's ideal for patients with suspected coronary artery disease, especially those with symptoms like chest pain or inconclusive stress tests, to determine if an intervention like stenting or bypass surgery is necessary.

View HeartFlow Analysis →

Choose Cardiomo if…

Choose Cardiomo if you require continuous, remote monitoring of heart health and vital signs for early detection of cardiovascular diseases and timely alerts. This medical-grade wearable is well-suited for individuals, particularly those aged 45 and above with existing heart issues, who need 24/7 tracking and immediate notifications to users, caregivers, and medical professionals in case of critical events.

View Cardiomo →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature HeartFlow Analysis Cardiomo
Pricing Contact vendor for pricing Contact for pricing
Deployment Cloud-based (AWS) Cloud-based with wearable device and mobile app
BAA Available Yes AI-estimated Unknown
FDA Status Yes AI-estimated Unknown
HIPAA Yes AI-estimated Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Cardiomo

Cardiomo offers a wearable patch and mobile app for continuous, real-time monitoring, which is generally considered user-friendly for patients, especially the elderly, and provides immediate alerts to caregivers. HeartFlow Analysis, while non-invasive, requires a CT scan and subsequent analysis, making it a less continuous and more clinician-driven process from the patient's perspective.

Clinical Value

HeartFlow Analysis

HeartFlow Analysis has extensive clinical validation with over 200 studies assessing over 365,000 patients, demonstrating high diagnostic accuracy and impact on clinical decision-making, including guiding revascularization procedures. Cardiomo, while offering continuous monitoring and early disease detection, has fewer publicly available large-scale clinical validation studies, with most being small-scale and short-duration.

Pricing & Value

HeartFlow Analysis

HeartFlow Analysis has established Category I CPT codes for its services, is covered by Medicare and most U.S. commercial payers, and has publicly available CMS payment rates, indicating clear reimbursement pathways and recognized value within the healthcare system. Cardiomo's current pricing details are not publicly available, and while it previously offered a device with a monthly subscription, its reimbursement landscape appears less established for broad clinical adoption.

Enterprise Readiness

HeartFlow Analysis

HeartFlow Analysis is deployed as a cloud-based solution (AWS) and has been adopted by over 1,800 institutions globally, indicating robust infrastructure and proven integration capabilities within healthcare systems. Cardiomo is also cloud-based with a mobile app, but its enterprise adoption and integration capabilities with large healthcare systems are less extensively documented in the provided information.

Innovation

Tie

Both tools demonstrate significant innovation in their respective domains. HeartFlow leverages AI and computational fluid dynamics to create personalized 3D models and FFRct analysis from CT scans, offering a non-invasive approach to diagnose CAD. Cardiomo innovates with a medical-grade wearable patch for continuous, real-time remote monitoring and AI-powered disease detection, addressing a different but equally important aspect of cardiac care.

Support & Docs

HeartFlow Analysis

HeartFlow provides comprehensive support including billing and reimbursement assistance, technology integration with PACS/EMR, educational materials for clinicians and patients, and peer-to-peer education. While Cardiomo offers real-time alerts and data for doctors and caregivers, specific details on structured support, documentation, and integration services for healthcare providers are not as extensively outlined.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature HeartFlow Analysis Cardiomo
Name HeartFlow Analysis Cardiomo
Company HeartFlow Cardiomo, Inc.
Tagline Decisive Coronary Care A medical-grade wearable device that monitors vital signs and uses an AI engine to detect cardiovascular diseases and provide life-saving alerts.
Description HeartFlow Analysis is a commercial-stage medical technology company providing software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease (CAD) by creating personalized 3D models of patients' coronary arteries from standard CT scans. Cardiomo offers a medical-grade wearable device and an AI-powered platform for continuous and remote heart health monitoring, designed to detect cardiovascular diseases and provide timely alerts to users and caregivers.
Key Features AI-powered 3D modeling of coronary arteries, Fractional Flow Reserve derived from CT (FFRct) analysis, Plaque Analysis (quantification and characterization), Roadmapu2122 Analysis for CCTA reading, Non-invasive diagnostic assessment, Personalized patient insights, Computational Fluid Dynamics (CFD) for blood flow simulation, High diagnostic accuracy Medical-grade wearable patch, Continuous vital sign monitoring (ECG, heart rate, respiration, skin temperature), AI-powered disease detection (arrhythmias, cardiovascular events), Real-time alerts and notifications, Mobile application (Android and iOS), HIPAA-compliant cloud analytics, Fall detection, Long battery life (up to 7-10 days)

Videos

Demos, reviews, and walkthroughs featuring HeartFlow Analysis and Cardiomo.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

HeartFlow Analysis is designed for seamless integration into the CCTA pathway, automatically and securely receiving CCTA scans for AI-enabled analysis of anatomy, plaque, and physiology, with results delivered directly into PACS and EMR systems. Cardiomo offers RESTful API, webhooks, and pre-built integrations to connect with existing platforms, aiming for seamless data exchange with EHRs for continuous patient monitoring data.
HeartFlow Analysis demonstrates high diagnostic performance for detecting coronary artery disease, with studies showing 87% accuracy, 90% sensitivity, and 86% specificity on a per-vessel basis for FFRct Analysis. Cardiomo's medical-grade biosensors achieve 99.2% clinical accuracy for continuous vital sign monitoring, with reported sensitivity for arrhythmia detection ranging from 84% to 95% in wearable devices.
HeartFlow Analysis is primarily suited for cardiology and radiology, focusing on diagnosing and managing coronary artery disease in symptomatic patients, particularly those with suspected CAD or stable chest pain. Cardiomo is designed for continuous and remote heart health monitoring, making it suitable for cardiology, geriatrics, and internal medicine, especially for detecting cardiovascular diseases and providing timely alerts to users and caregivers.
HeartFlow Analysis aims to increase efficiency for CT readers with its Roadmap Analysis, which is proven to reduce inter-reader variability and helps identify stenoses, suggesting a streamlined learning process for interpreting CCTA. Cardiomo emphasizes its user-friendly nature and ease of integration, implying a relatively low learning curve for both patients and healthcare providers in utilizing the wearable device and mobile application.
HeartFlow has been adopted by over 1,400 institutions globally, including 80% of the top 50 heart hospitals in the U.S., indicating its suitability for multi-site rollouts and integration into large hospital systems. Cardiomo's cloud-based platform with a wearable device and mobile app is inherently designed for remote monitoring, which can facilitate multi-site deployment and management of patient data across different locations.

Backers

Who funded each tool's parent company.

HeartFlow Analysis

Cardiomo

AI Tool Finder
AI-powered search. Results may not be comprehensive.